Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XePOHCAS xenon in post-cardiac arrest syndrome after out-of-hospital cardiac arrest
2017-002514-32Phase 3Completed
- Sponsor
- NeuroproteXeon
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxygen in post-cardiac arrest syndrome (PCAS) (2 arms), sponsored by NeuroproteXeon. Primary endpoints: Good functional outcome at Day 30 and Good functional outcome at Day 90. Started Jul 2018; status: completed.
02
Drugs
oxygen
03
Conditions
post-cardiac arrest syndrome (PCAS)
Beyond the preview
Go deeper on 2017-002514-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002514-32.